Immunoelectrophoresis method for diagnosing and differentiating cancer using lectins

• US 4,791,066 A
• Filed: 08/06/1985
• Issued: 12/13/1988
• Est. Priority Date: 08/07/1984
• Status: Expired due to Term

• Current Assignee: Kyowa Medex Company Limited 6-1 Ohtemachi Itchome Chiyoda-Ku Tokyo Japan
• Original Assignee: Kyowa Medex Co., Ltd. (Resonac Holdings Corp.)
• Inventors: Ishiguro, Tatsuya
• Primary Examiner(s): Kepplinger, Esther M.
• Assistant Examiner(s): Wieder, Stephen C.
• Application Number:
  US06/762,970
• Time in Patent Office: 1,225 Days
• Field of Search: 436/501, 436/514, 436/516, 436/827, 435/7
• US Class Current: 436/516
• CPC Class Codes: G01N 33/561 Immunoelectrophoresis
• CPC Class Codes: G01N 33/57469 involving tumor associated glycolinkage, i.e. TAG
• CPC Class Codes: G01N 33/57473 involving carcinoembryonic antigen, i.e. CEA
• CPC Class Codes: G01N 33/57476 involving oncofetal proteins
• CPC Class Codes: Y10S 436/813 Cancer
• CPC Class Codes: Y10S 436/827 Lectins

Abstract

Disclosed is a method for diagnosing and differentiating cancer by qualitative and quantitative determination according to an immuno-serological assay of cancer-related antigens in a body fluid, particularly glycoprotein, glycolipid and glycoantigen produced by cancerization or dedifferentiation of normal cells.

Claims

1. A method of differentiating primary hepatic carcinoma from metastatic hepatic carcinoma, comprising obtaining a sample of a body fluid from a patient suspected of having hepatic carcinoma, assaying said sample by means of cross-immunoaffinoelectrophoresis on each one of a pair of lectins selected from the group consisting of ConA-LCH, ConA-PHA-E, RCA-I-LCH, RCA-I-BSA-II and BSA-II-LCH, for the presence of α

-fetoprotein specific fraction binding patterns; and

differentiating primary hepatic carcinoma from metastatic hepatic carcinoma based on the resulting specific fraction binding patterns.

2. The method according to claim 1, wherein coloring after the cross-immunoaffinoelectrophoresis is carried out by a highly sensitive assay using peroxidase-labelled protein A, 4-methoxy-1-naphtol and hydrogen peroxide.

3. A method of differentiating oophoroma from metastatic hepatic carcinoma, comprising obtaining a sample of a body fluid from a patient suspected of having oophoroma or metastatic hepatic carcinoma, assaying said sample by means of crossed-immunoaffinoelectrophoresis on each one of a pair of lectins selected form the group consisting of PHA-E-RCA-I and PHA-E-BSA-II, for the presence of α

-fetoprotein specific fraction binding patterns; and

differentiating oophoroma from metastatic hepatic carcinoma based on the resulting specific fraction binding patterns.

4. The method according to claim 3 wherein coloring after the cross-immunoaffinoelectrophoresis is carried out by a highly sensitive assay using peroxidase-labelled protein A, 4-methoxy-1-naphthol and hydrogen peroxide.